[1] |
WENG Junyong, YE Zilan, ZHANG Ruoxin, LIU Qi, LI Xinxiang.
Exploring the guiding role of the number of adverse pathological features in risk stratification for recurrence of stage Ⅰ-Ⅲ colorectal cancer: a retrospective cohort study of 9 875 cases
[J]. China Oncology, 2024, 34(6): 527-536.
|
[2] |
LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan.
Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications
[J]. China Oncology, 2024, 34(4): 368-379.
|
[3] |
ZHANG Lingling, WANG Xiangyi, WEI Xing, LIN Li, TANG Chuanhao, LIANG Jun.
A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis
[J]. China Oncology, 2023, 33(8): 776-781.
|
[4] |
TANG Duocai, ZHOU Shukui, ZHANG Guiyin, LIU Lei, LIAO Hong.
Analysis of risk factors of recurrence in non-muscle invasive bladder cancer patients after initial transurethral resection of bladder tumor
[J]. China Oncology, 2023, 33(5): 478-483.
|
[5] |
SU Chunxia, ZHOU Caicun.
Important clinical research progress in lung cancer in 2022
[J]. China Oncology, 2023, 33(3): 218-227.
|
[6] |
DONG Xiaohuan, LIU Jun, LI Hongxuan, CHENG Yan, LI Yue, YU Wen, CAI Xuwei, FU Xiaolong.
Preliminary study on involving field irradiation radiotherapy in neoadjuvant chemoradiotherapy for esophageal cancer
[J]. China Oncology, 2023, 33(3): 267-273.
|
[7] |
HE Liyuan, WANG Yudong.
Research progress of ALK kinase domain drug resistance mutation and its future countermeasures
[J]. China Oncology, 2022, 32(8): 736-746.
|
[8] |
CAO Mengxuan, HU Can, ZHANG Yanqiang, HUANG Ling, DU Yian, YU Pengcheng, ZHANG Ruolan, XU Zhiyuan, CHENG Xiangdong.
Analysis of risk factors of early recurrence and metastasis after radical resection of gastric cancer
[J]. China Oncology, 2022, 32(7): 588-595.
|
[9] |
HONG Yaping, HUANG Yunjian, HUANG Zhangzhou, CHEN Shengjia, ZHONG Qiaofeng, ZENG Hongfu, ZHUANG Wu.
Efficacy and prognostic predictors of first-generation EGFR TKI-targeted therapy in patients with EGFR-mutated advanced non-small cell lung cancer
[J]. China Oncology, 2022, 32(7): 624-634.
|
[10] |
SU Chunxia, ZHOU Caicun.
Current status and future directions of immunotherapy for advanced non-small cell lung cancer
[J]. China Oncology, 2022, 32(6): 478-486.
|
[11] |
YU Silai, NI Jianjiao, ZHU Zhengfei.
Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects
[J]. China Oncology, 2022, 32(6): 487-498.
|
[12] |
FU Yuanyuan, HOU Runping, FU Xiaolong.
Research progress in predicting the risk of lymphatic or hematologic metastasis based on chest CT in early non-small cell lung cancer
[J]. China Oncology, 2022, 32(4): 343-350.
|
[13] |
LI Ting, XU Yu, JIA Dongdong, LIAO Zhichao, SUN Wei, WU Haixiao, REN Zhiwu, ZHAO Jun, XING Ruwei, TENG Sheng, YANG Yun, CHEN Yong, LI Tao, YANG Jilong.
Adjuvant therapy with anti-PD-1 antibody vs targeted therapy for patients with resected stage Ⅲ malignant melanoma: a real-world data analysis from China centers
[J]. China Oncology, 2022, 32(12): 1147-1157.
|
[14] |
ZHAO Mingming, WANG Tianyou, WANG Chao.
Progress in menopausal hormone therapy for postoperative patients with gynecological malignant cancer
[J]. China Oncology, 2022, 32(11): 1098-1104.
|
[15] |
LIN Yi, WANG Ce, KANG Xun, KANG Zhuang, CHEN Feng, JIANG Bo, LI Wenbin.
Screening recurrent glioblastoma-related genes and analyzing their gene expressions in association with clinicopathological parameters and prognosis
[J]. China Oncology, 2022, 32(1): 13-23.
|